Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

April 26, 2022

AstraZeneca AB et al v. Mylan Pharmaceuticals Inc. et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. December 15, 2022

    Judge Breathes 6 Months Of Life Into AstraZeneca Patent

    A day after hearing arguments from Mylan lawyers that AstraZeneca should be bound to a January 2023 expiration date of a patent protecting the blockbuster asthma treatment Symbicort, a federal judge in West Virginia ruled Thursday that AstraZeneca deserved at least six months more of market exclusivity.

2 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login